| Literature DB >> 34305198 |
Carla Monteiro Leal1,2, Suzana Guimarães Leitão3, Romain Sausset2,4, Simony C Mendonça2, Pedro H A Nascimento2, Caio Felipe de Araujo R Cheohen5, Maria Eduarda A Esteves6, Manuela Leal da Silva5,6, Tayssa Santos Gondim7, Maria Eduarda S Monteiro7, Amanda Resende Tucci7, Natália Fintelman-Rodrigues8,9, Marilda M Siqueira7, Milene Dias Miranda7, Fernanda N Costa2, Rosineide C Simas10, Gilda Guimarães Leitão2.
Abstract
The novel coronavirus SARS-CoV-2 has been affecting the world, causing severe pneumonia and acute respiratory syndrome, leading people to death. Therefore, the search for anti-SARS-CoV-2 compounds is pivotal for public health. Natural products may present sources of bioactive compounds; among them, flavonoids are known in literature for their antiviral activity. Siparuna species are used in Brazilian folk medicine for the treatment of colds and flu. This work describes the isolation of 3,3',4'-tri-O-methyl-quercetin, 3,7,3',4'-tetra-O-methyl-quercetin (retusin), and 3,7-di-O-methyl-kaempferol (kumatakenin) from the dichloromethane extract of leaves of Siparuna cristata (Poepp. & Endl.) A.DC., Siparunaceae, using high-speed countercurrent chromatography in addition to the investigation of their inhibitory effect against SARS-CoV-2 viral replication. Retusin and kumatakenin inhibited SARS-CoV-2 replication in Vero E6 and Calu-3 cells, with a selective index greater than lopinavir/ritonavir and chloroquine, used as control. Flavonoids and their derivatives may stand for target compounds to be tested in future clinical trials to enrich the drug arsenal against coronavirus infections. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43450-021-00162-5. © Sociedade Brasileira de Farmacognosia 2021.Entities:
Keywords: Coronavirus; Countercurrent chromatography; Mass spectrometry; O-Methyl flavonoids; Siparunaceae
Year: 2021 PMID: 34305198 PMCID: PMC8294293 DOI: 10.1007/s43450-021-00162-5
Source DB: PubMed Journal: Rev Bras Farmacogn ISSN: 0102-695X Impact factor: 2.010
CC50, EC50, and SI values for 3,3′,4′-tri-O-methyl-quercetin, 1; 3,7,3′,4′-tetra-O-methyl-quercetin (retusin), 2; 3,7-di-O-methyl-kaempferol (kumatakenin) 3; LPV/RTV; and CLQ
| Vero E6 | Calu-3 | |||||
|---|---|---|---|---|---|---|
| CC50 (µM) | EC50 (µM) | SI | CC50 (µM) | EC50 (µM) | SI | |
| 3,3′,4′-Tri- | 3000 ± 150 | NA | NA | 3500 ± 130 | NA | NA |
| 3,7-Di- | 2000 ± 230 | 10 ± 0.7 | 200 | 2080 ± 135 | 0.3 ± 0.02 | 6933 |
| 3,7,3′,4′-Tetra- | 4575 ± 300 | 0.4 ± 0.05 | 11,438 | 5000 ± 200 | 0.6 ± 0.06 | 8333 |
| LPV/RTV | 91 ± 3 | 10 ± 3 | 9.1 | 100 ± 3 | 5 ± 0.5 | 20 |
| CLQ | 1664 ± 75 | 1 ± 0.15 | 1664 | 500 ± 50 | NA | NA |
| > 200 µg/ml | < 31.25 µg/ml | > 6.4 | > 200 µg/ml | < 31.25 µg/ml | > 6.4 | |
CC, the concentration required to reduce normal, non-infected cell viability by 50%. The values represent the mean of duplicate samples from three independent experiments. EC, the concentration required to reduced inhibition of viral infection-induced cytopathogenicity by 50%. The values represent the mean of duplicate samples from three independent experiments
SI selective index determined by the ratio between CC50 and EC50, LPV/RTV the combination of lopinavir/ritonavir, CLQ chloroquine, NA not applicable
Fig. 1Interaction of SARS-CoV-2 3CLpro protease residues with retusin (2). A Map of the interaction of residues. B Protease 3CLpro (PDBid: 6XQT) in gray and residues within a radius of proximity equal to 5 Å of the ligand, represented by sticks. The ligand is in orange, and the catalytic dyad residues His41 and Cys145 and the residue Glu166 are in lavender. C The representation shows the interaction of these residues with the ligand
Energy docking values for 3CLpro and PLpro hydrogen-bonding interaction with compounds 1–3
| Compound | 3CLpro | PLpro | ||||||
|---|---|---|---|---|---|---|---|---|
| Affinity for the best distance mode (kcal/mol) | Mode | Distance | Distance | Distance | Affinity for the best distance mode (kcal/mol) | Mode | Distance | |
| − 6.5 | 9 | – | 2.77 | – | − 7.1 | 1 | 2.2 | |
| − 6.3 | 6 | 2.60 | 2.68 | – | − 5.5 | 7 | 1.9 | |
| − 7.2 | 3 | – | 3.01 | 2.19 | − 5.7 | 7 | 2.1 | |
| LPVa | − 5.1 | 9 | 2.92 | – | – | − 5.7 | 9 | 1.8 |
| RTVb | − 8.1 | 11 | 2.41 | 2.68 | 2.42 | − 6.9 | 2 | 1.6 |
| CLQc | − 6.4 | 1 | – | – | 2.11 | − 5.9 | 8 | 1.1 |
aPositive control: lopinavir
bPositive control: ritonavir
cPositive control: chloroquine
Fig. 2Interaction of SARS-CoV-2 PLpro residues with retusin (2). A Map of the interaction of residues. B Protease PLpro (PDBid:7JRN) in gray and residues within a radius of proximity equal to 5 Å of the ligand, represented by sticks. The ligand is in orange, and the residue Tyr268 is in lavender. C This representation shows the interaction of this residue with the ligand